Medium materiality6/10
Barclays Downgrades Forte Biosciences Inc. (FBRX) to Equalweight
Why it may matterVerify against the original reporting
Bearish downgrade; minimal upside implied by target.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Barclays downgrades Forte Biosciences to Equalweight with a $77 target; current price is $76.50.
- Barclays downgrades FBRX to Equalweight; target $77 vs price $76.50.
Key facts
- 01
Target: $77
- 02
Posted price: $76.5
- 03
Analyst firm: Barclays
- 04
Analyst: Etzer Darout
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.